Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

NCT05204160 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped slow accrual

Conditions

Plasma Cell Myeloma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Emory University

Collaborators

[object Object]
[object Object]